EVOQ Remedies Ltd (EVOQ)

Currency in INR
3.60
+0.02(+0.56%)
Closed·

EVOQ Financial Summary

Key Ratios

P/E Ratio71.5
Price/Book0.12
Debt / Equity6.53%
Return on Equity0.25%
Dividend Yield0.00%
EBITDA1.77M
Fair ValueUnlock
Fair Value UpsideUnlock

Statements Highlights

Period Ending:
2019
31/03
2020
31/03
2021
31/03
2022
31/03
2023
31/03
2024
31/03
2025
31/03
* In Millions of INR (except for per share items)

Earnings

Latest Release
Apr 10, 2025
EPS / Forecast
0.90 / --
Revenue / Forecast
141.61M / --
EPS Revisions
Last 90 days

FAQ

What were EVOQ Remedies's earnings for the latest quarter?

The EVOQ Remedies EPS (TTM) is 0.04. EVOQ Remedies reported sales of 141.61, net income of 17.13, and EPS of 0.90 for the latest quarter.

What was EVOQ Remedies's net income for the latest quarter?

EVOQ Remedies's net income for the latest quarter was 17.13.

How did EVOQ Remedies's performance compare year-over-year in the latest quarter?

The company's revenue moved from 0.11 in the previous quarter to 141.61 in the latest quarter, and net income moved from -16.24 to 17.13 compared to the previous quarter.

What is EVOQ Remedies's net profit margin on a TTM basis?

EVOQ Remedies's trailing twelve months (TTM) net profit margin is 0.62%.

How does EVOQ Remedies's debt to equity ratio compare to industry standards?

EVOQ Remedies's total debt-to-equity ratio is 6.53%.

What is EVOQ Remedies's return on investment on a TTM basis?

EVOQ Remedies's trailing twelve months (TTM) return on investment (ROI) is 0.25%.

Did EVOQ Remedies gain or lose cash last quarter?

In the latest quarter, EVOQ Remedies's net change in cash was -0.45 million.

What were EVOQ Remedies's total assets and liabilities in the latest quarter?

As of the latest quarter, EVOQ Remedies reported total assets of 500.09 million and total liabilities of 54.73 million.

How has EVOQ Remedies's total revenue grown this year?

EVOQ Remedies's total revenue was 0.11 in the previous quarter and 141.61 in the latest quarter.

What is EVOQ Remedies's gross margin on a TTM basis?

EVOQ Remedies's trailing twelve months (TTM) gross margin is 7.69%.

What was EVOQ Remedies's revenue per share for the latest quarter?

EVOQ Remedies's revenue per share for the latest quarter was 298.95.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.